CONTINUATION TRIAL OF LYMPHOSTAT-B ANTIBODY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项在LBSL02第二阶段研究中取得满意反应的SLE受试者的LymphStat-B多中心、开放标签、持续试验。受试者将每28天静脉注射10毫克/公斤的LymphStat-B，持续1至2小时。第一次输液将超过2个小时。如果没有输液反应，则第二剂输液将超过1.5小时。如果没有输液反应，则第三次及以后的剂量将在1小时内输注。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, open-label, continuation trial of LymphoStat-B in SLE subjects who achieved a satisfactory response in the Phase 2 study of LBSL02. Subjects will receive 10 mg/kg of LymphStat-B every 28 days intravenously over a period of 1 to 2 hours. The first infusion will be given over 2 hours. If no infusion reactions occur, then the 2nd dose will be infused over 1.5 hours. If no infusion reactions occur, then the 3rd and subsequent doses will be infused over 1 hour.